

Accepted Manuscript

Infections in moderate-to-severe psoriasis patients treated with biological drugs compared to classic systemic drugs: Findings from the BIOBADADERM registry

Paula Dávila-Seijo, MD, Esteban Dauden, PhD, M.A. Descalzo, PhD, Gregorio Carretero, PhD, José-Manuel Carrascosa, PhD, Francisco Vanaclocha, MD, Francisco-José Gómez-García, PhD, Pablo De la Cueva-Dobao, PhD, Enrique Herrera-Ceballos, PhD, Isabel Belinchón, PhD, José-Luis López-Estebanz, MD, Merce Alsina, MD, José-Luis Sánchez-Carazo, MD, Marta Ferrán, MD, Rosa Torrado, MD, Carlos Ferrandiz, PhD, Raquel Rivera, MD, Mar Llamas, MD, Rafael Jiménez-Puya, MD, Ignacio García-Doval, PhD

PII: S0022-202X(16)32459-9

DOI: [10.1016/j.jid.2016.08.034](https://doi.org/10.1016/j.jid.2016.08.034)

Reference: JID 539

To appear in: *The Journal of Investigative Dermatology*

Received Date: 6 May 2016

Revised Date: 29 July 2016

Accepted Date: 31 August 2016

Please cite this article as: Dávila-Seijo P, Dauden E, Descalzo M, Carretero G, Carrascosa J-M, Vanaclocha F, Gómez-García F-J, De la Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, López-Estebanz J-L, Alsina M, Sánchez-Carazo J-L, Ferrán M, Torrado R, Ferrandiz C, Rivera R, Llamas M, Jiménez-Puya R, García-Doval I, and the BIOBADADERM Study Group, Infections in moderate-to-severe psoriasis patients treated with biological drugs compared to classic systemic drugs: Findings from the BIOBADADERM registry, *The Journal of Investigative Dermatology* (2016), doi: 10.1016/j.jid.2016.08.034.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Infections in moderate-to-severe psoriasis patients treated with biological drugs compared to classic systemic drugs: Findings from the BIOBADADERM registry

Paula Dávila-Seijo, MD¹⁻¹⁵, Esteban Dauden, PhD², MA Descalzo, PhD¹, Gregorio Carretero, PhD³, José-Manuel Carrascosa, PhD⁴, Francisco Vanaclocha, MD⁵, Francisco-José Gómez-García, PhD⁶, Pablo De la Cueva-Dobao, PhD⁷, Enrique Herrera-Ceballos, PhD⁸, Isabel Belinchón, PhD⁹, José-Luis López-Esteban, MD¹⁰, Merce Alsina, MD¹¹, José-Luis Sánchez-Carazo, MD¹², Marta Ferrán, MD¹³, Rosa Torrado, MD³, Carlos Ferrandiz, PhD⁴, Raquel Rivera, MD⁵, Mar Llamas, MD², Rafael Jiménez-Puya, MD⁶, Ignacio García-Doval, PhD^{1,14}, and the BIOBADADERM Study Group.

Running head: Risk of infections in systemic psoriasis therapy

Abstract word count: 198

Text word count: 3376

References: 29 references

Tables and figures: 5 tables

IRB status: Approved (Hospital Universitario 12 de Octubre, 07/216)

Not previously presented

¹ Research Unit. Fundación Academia Española de Dermatología y Venereología, Madrid, Spain.

² Dermatology department. Hospital Universitario La Princesa, Madrid, Spain.

Download English Version:

<https://daneshyari.com/en/article/5649779>

Download Persian Version:

<https://daneshyari.com/article/5649779>

[Daneshyari.com](https://daneshyari.com)